Asset
Lorundrostat Hydrobromide
Mineralys Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05001945 | phase2 | completed | 2021-07-01 | 2022-09-07 | Mineralys Therapeutics Inc. | Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension |
FDA applications (0)
This company has no applications containing this asset.